The Oxford Drug Discovery Institute is uniquely placed to draw on rich resources from across the drug discovery landscape.
From close ties with the Structural Genomics Consortium that enable rational drug design, all the way through to biomarker development to demonstrate target engagement and facilitate clinical stratification, our drug discovery expertise will translate basic biology into tangible benefits for patients.
We have access to extensive compound libraries, both in-house within The Target Discovery Institute and through partnerships with the European Lead Factory and NuEvolution. In addition, our collaboration with the Structural Genomics Consortium ensures access to epigenetic-focused compounds and fragment libraries.
Alongside our call for novel targets implicated in Alzheimer’s and other causes of dementia, the University of Oxford houses a state-of-the-art screening facility, which forms part of the £8 million UK-National Phenotypic Screening Centre. Phenotypic screening is a powerful method for drug discovery because it offers the opportunity to go beyond a focus on single drug targets and broaden the search to pathways involved in disease progression. Together with its counterpart at the University of Dundee, the screening facility represents the most advanced in the UK. The system integrates a GE InCell 6000 and Perkin Elmer Envision imagers, with a compound management system consisting of Labcyte Echo 555 with an online storage capacity of 462 compound and cell plates.
Target development facilities
The Oxford Drug Discovery Institute is integrated within The Target Discovery Institute and as such our scientists will have access to a broad range of core expertise, including advanced bioimaging, flow cytometry, mass spectrometry and chemical biology.
Existing expertise in the biology and chemical biology of epigenetic targets (Oleg Fedorov, Kilian Huber, Paul Brennan / SGC) and the ubiquitin-proteasome system (Kessler group), in combination with already established chemical proteomics technology, will help to accelerate target development in dementia.
The Oxford Drug Discovery Institute’s medicinal chemists will have access to a bespoke chemistry suite in order to create chemical probes to interrogate target function and produce lead compounds. These facilities include Biotage MPLC purification systems, 400 MHz NMR and extensive x-ray crystallography facilities at the Structural Genomics Consortium.
These facilities are equipped for routine organic synthesis and parallel chemistry, including with automated purification and analysis systems and a 400MHz NMR. Access to extensive X-ray crystallography facilities at the Structural Genomics Consortium and Diamond Light Source allow use of structural data in compound design.